EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

Also called NCT04743453

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 211 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04743453
Other papers using this trial's data
  • The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled Trial Transplantation, 2026-07-01 DOI, PubMed 42102257

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04743453. Randomized; double masking; primary purpose treatment. Start 2021-08-17 (actual); primary completion 2024-09-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.
Condition
Kidney Transplantation
Condition
Diabetes Mellitus, Type 2
Condition
Diabetes Complications
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
University of Sao Paulo General Hospital (class: other)
Collaborator
Federal University of São Paulo (class: other)

Record details

Record id
cardio:ct-nct04743453
Content hash
acc841909639916f14a2164f94f39dcf9f6dbcbe6116a2e44a622126d0d60529